Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells"

Bilada Bilican; Andrea Serio; Sami J Barmada; Agnes Lumi Nishimura; Gareth J Sullivan; Monica Carrasco; Hemali P Phatnani; Clare A Puddifoot; David Story; Judy Fletcher; In-Hyun Park; Brad A Friedman; George Q Daley; David J A Wyllie; Giles E Hardingham; Ian Wilmut; Steven Finkbeiner; Tom Maniatis; Christopher E Shaw; Siddharthan Chandran

doi:10.1126/scitranslmed.3005065

Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells"

Bilada Bilican, Andrea Serio, Sami J Barmada, Agnes Lumi Nishimura, Gareth J Sullivan, Monica Carrasco, Hemali P Phatnani, Clare A Puddifoot, David Story, Judy Fletcher, In-Hyun Park, Brad A Friedman, George Q Daley, David J A Wyllie, Giles E Hardingham, Ian Wilmut, Steven Finkbeiner, Tom Maniatis, Christopher E Shaw, Siddharthan Chandran

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs) for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need for complementary assays to detect small, but potentially important, phenotypic differences between control iPSC lines and those carrying disease mutations.

Original language	English
Pages (from-to)	188le2
Journal	Science Translational Medicine
Volume	5
Issue number	188
DOIs	https://doi.org/10.1126/scitranslmed.3005065
Publication status	Published - 5 Jun 2013

Keywords

Amyotrophic Lateral Sclerosis/pathology
Drug Evaluation, Preclinical/methods
Humans
Induced Pluripotent Stem Cells/cytology
Motor Neurons/cytology

Access to Document

10.1126/scitranslmed.3005065

Cite this

Bilican, B., Serio, A., Barmada, S. J., Nishimura, A. L., Sullivan, G. J., Carrasco, M., Phatnani, H. P., Puddifoot, C. A., Story, D., Fletcher, J., Park, I.-H., Friedman, B. A., Daley, G. Q., Wyllie, D. J. A., Hardingham, G. E., Wilmut, I., Finkbeiner, S., Maniatis, T., Shaw, C. E., & Chandran, S. (2013). Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells". Science Translational Medicine, 5(188), 188le2. https://doi.org/10.1126/scitranslmed.3005065

@article{fe181d72ec7e48c7a06fba6b8bc34462,

title = "Comment on {"}Drug screening for ALS using patient-specific induced pluripotent stem cells{"}",

abstract = "Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs) for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need for complementary assays to detect small, but potentially important, phenotypic differences between control iPSC lines and those carrying disease mutations.",

keywords = "Amyotrophic Lateral Sclerosis/pathology, Drug Evaluation, Preclinical/methods, Humans, Induced Pluripotent Stem Cells/cytology, Motor Neurons/cytology",

author = "Bilada Bilican and Andrea Serio and Barmada, {Sami J} and Nishimura, {Agnes Lumi} and Sullivan, {Gareth J} and Monica Carrasco and Phatnani, {Hemali P} and Puddifoot, {Clare A} and David Story and Judy Fletcher and In-Hyun Park and Friedman, {Brad A} and Daley, {George Q} and Wyllie, {David J A} and Hardingham, {Giles E} and Ian Wilmut and Steven Finkbeiner and Tom Maniatis and Shaw, {Christopher E} and Siddharthan Chandran",

year = "2013",

month = jun,

day = "5",

doi = "10.1126/scitranslmed.3005065",

language = "English",

volume = "5",

pages = "188le2",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "188",

}

Bilican, B, Serio, A, Barmada, SJ, Nishimura, AL, Sullivan, GJ, Carrasco, M, Phatnani, HP, Puddifoot, CA, Story, D, Fletcher, J, Park, I-H, Friedman, BA, Daley, GQ, Wyllie, DJA, Hardingham, GE, Wilmut, I, Finkbeiner, S, Maniatis, T, Shaw, CE & Chandran, S 2013, 'Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells"', Science Translational Medicine, vol. 5, no. 188, pp. 188le2. https://doi.org/10.1126/scitranslmed.3005065

TY - JOUR

T1 - Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells"

AU - Bilican, Bilada

AU - Serio, Andrea

AU - Barmada, Sami J

AU - Nishimura, Agnes Lumi

AU - Sullivan, Gareth J

AU - Carrasco, Monica

AU - Phatnani, Hemali P

AU - Puddifoot, Clare A

AU - Story, David

AU - Fletcher, Judy

AU - Park, In-Hyun

AU - Friedman, Brad A

AU - Daley, George Q

AU - Wyllie, David J A

AU - Hardingham, Giles E

AU - Wilmut, Ian

AU - Finkbeiner, Steven

AU - Maniatis, Tom

AU - Shaw, Christopher E

AU - Chandran, Siddharthan

PY - 2013/6/5

Y1 - 2013/6/5

N2 - Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs) for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need for complementary assays to detect small, but potentially important, phenotypic differences between control iPSC lines and those carrying disease mutations.

AB - Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs) for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need for complementary assays to detect small, but potentially important, phenotypic differences between control iPSC lines and those carrying disease mutations.

KW - Amyotrophic Lateral Sclerosis/pathology

KW - Drug Evaluation, Preclinical/methods

KW - Humans

KW - Induced Pluripotent Stem Cells/cytology

KW - Motor Neurons/cytology

U2 - 10.1126/scitranslmed.3005065

DO - 10.1126/scitranslmed.3005065

M3 - Article

C2 - 23740897

SN - 1946-6234

VL - 5

SP - 188le2

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 188

ER -

Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells"

Abstract

Keywords

Access to Document

Fingerprint

Cite this